Tackling pharmacological response heterogeneity by PBPK modeling to advance precision medicine productivity of nanotechnology and genomics therapeutics

References

• Dollery CT. Clinical pharmacology – the first 75 years and a view of the future. Br J Clin Pharmacol. 2006;61(6):650–665.
   Web of Science ®Google Scholar
• Srivastava AK, Hollingshead MG, Govindharajulu JP, et al. Molecular pharmacodynamics-guided scheduling of biologically effective doses: a drug development paradigm applied to MET tyrosine kinase inhibitors. Mol Cancer Ther. 2018 Mar;17(3):698–709.
   PubMed Web of Science ®Google Scholar
• Vizirianakis IS, Fatouros DG. Personalized nanomedicine: paving the way to the practical clinical utility of genomics and nanotechnology advancements. Adv Drug Deliv Rev. 2012 Oct;64(13):1359–1362.
   PubMed Web of Science ®Google Scholar
• Yamazaki S. Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib. AAPS J. 2013 Apr;15(2):354–366.
   PubMed Web of Science ®Google Scholar
• Cheng F. In silico oncology drug repositioning and polypharmacology. Methods Mol Biol. 2019;1878:243–261.
   PubMedGoogle Scholar
• Danhof M. Systems pharmacology – towards the modeling of network interactions. Eur J Pharm Sci. 2016 Oct;30(94):4–14.
   Google Scholar
• Hansen J, Iyengar R. Computation as the mechanistic bridge between precision medicine and systems therapeutics. Clin Pharmacol Ther. 2013 Jan;93(1):117–128.
   PubMed Web of Science ®Google Scholar
• Prasad B, Vrana M, Mehrotra A, et al. The promises of quantitative proteomics in precision medicine. J Pharm Sci. 2017 Mar;106(3):738–744.
   PubMed Web of Science ®Google Scholar
• Vizirianakis IS. Harnessing pharmacological knowledge for personalized medicine and pharmacotyping: challenges and lessons learned. World J Pharmacol. 2014 Dec 9;3(4):110–119.
   Google Scholar
• Rowland M, Balant L, Peck C Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29–30, 2002). AAPS Pharm Sci. 2004 Feb 9;6(1):E6.
   PubMedGoogle Scholar
• Teorell T. Kinetics of distribution of substances administered to the body. 11. The intravascular modes of administration. Arch Int Pharmacodyn Ther. 1937;57:226–240.
   Google Scholar
• Teorell T. Kinetics of distribution of substances administered to the body. I. The extravascular modes of administration. Arch Int Pharmacodyn Ther. 1937;57:205–225.
   Google Scholar
• Wagner JG. History of pharmacokinetics. Pharmacol Ther. 1981;12(3):537–562.
   PubMed Web of Science ®Google Scholar
• Widmark E, Tandberg J. Uber die Bedingungen fur die Akkumulation indifferenter narkoliken theoretische Bereckerunger. Biochem Z. 1924;147:358–369.
   Google Scholar
• Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol. 2011;51:45–73.
   PubMed Web of Science ®Google Scholar
• Chetty M, Johnson TN, Polak S, et al. Physiologically based pharmacokinetic modelling to guide drug delivery in older people. Adv Drug Deliv Rev. 2018;135:85–96.
   PubMed Web of Science ®Google Scholar
• Devoldere J, Dewitte H, De Smedt SC, et al. Evading innate immunity in nonviral mRNA delivery: don‘t shoot the messenger. Drug Discov Today. 2016 Jan;21(1):11–25.
   PubMed Web of Science ®Google Scholar
• Nagarajan N, Dupret-Bories A, Karabulut E, et al. Enabling personalized implant and controllable biosystem development through 3D printing. Biotechnol Adv. 2018;36(2):521–533.
   PubMed Web of Science ®Google Scholar
• Rodrigues T, Kundu B, Silva-Correia J, et al. Emerging tumor spheroids technologies for 3D in vitro cancer modeling. Pharmacol Ther. 2018;184:201–211.
   PubMed Web of Science ®Google Scholar
• Sahin U, Kariko K, Tureci O. mRNA-based therapeutics–developing a new class of drugs. Nat Rev Drug Discov. 2014 Oct;13(10):759–780.
   PubMed Web of Science ®Google Scholar
• Krauss M, Tappe K, Schuppert A, et al. Bayesian population physiologically-based pharmacokinetic (PBPK) approach for a physiologically realistic characterization of interindividual variability in clinically relevant populations. PLoS One. 2015;10(10):e0139423.
   PubMed Web of Science ®Google Scholar
• Jamei M. Recent advances in development and application of physiologically-based pharmacokinetic (PBPK) models: a transition from academic curiosity to regulatory acceptance. Curr Pharmacol Rep. 2016;2:161–169.
   PubMedGoogle Scholar
• Hsieh NH, Reisfeld B, Bois FY, et al. Applying a global sensitivity analysis workflow to improve the computational efficiencies in physiologically-based pharmacokinetic modeling. Front Pharmacol. 2018;9:588.
   PubMed Web of Science ®Google Scholar
• Marsousi N, Desmeules JA, Rudaz S, et al. Usefulness of PBPK modeling in incorporation of clinical conditions in personalized medicine. J Pharm Sci. 2017 Sep;106(9):2380–2391.
   PubMed Web of Science ®Google Scholar
• Jones HM, Parrott N, Jorga K, et al. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet. 2006;45(5):511–542.
   PubMed Web of Science ®Google Scholar
• Ferl GZ, Theil FP, Wong H. Physiologically based pharmacokinetic models of small molecules and therapeutic antibodies: a mini-review on fundamental concepts and applications. Biopharm Drug Dispos. 2016 Mar;37(2):75–92.
   PubMed Web of Science ®Google Scholar
• Leong R, Vieira ML, Zhao P, et al. Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. Clin Pharmacol Ther. 2012 May;91(5):926–931.
   PubMed Web of Science ®Google Scholar
• Krauss M, Burghaus R, Lippert J, et al. Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification. In Silico Pharmacol. 2013;1:6.
   PubMedGoogle Scholar
• Sharma RP, Schuhmacher M, Kumar V. The development of a pregnancy PBPK Model for Bisphenol A and its evaluation with the available biomonitoring data. Sci Total Environ. 2018 May;15(624):55–68.
   Google Scholar
• Ke AB, Greupink R, Abduljalil K. Drug dosing in pregnant women: challenges and opportunities in using physiologically based pharmacokinetic modeling and simulations. CPT Pharmacometrics Syst Pharmacol. 2018 Feb;7(2):103–110.
   PubMedGoogle Scholar
• Scotcher D, Jones CR, Galetin A, et al. Delineating the role of various factors in renal disposition of digoxin through application of physiologically based kidney model to renal impairment populations. J Pharmacol Exp Ther. 2017 Mar;360(3):484–495.
   PubMed Web of Science ®Google Scholar
• Li R, Barton HA, Maurer TS. A mechanistic pharmacokinetic model for liver transporter substrates under liver cirrhosis conditions. CPT Pharmacometrics Syst Pharmacol. 2015 Jun;4(6):338–349.
   PubMedGoogle Scholar
• Schlender JF, Meyer M, Thelen K, et al. Development of a whole-body physiologically based pharmacokinetic approach to assess the pharmacokinetics of drugs in elderly individuals. Clin Pharmacokinet. 2016 Dec;55(12):1573–1589.
   PubMed Web of Science ®Google Scholar
• Zhao P, Vieira Mde L, Grillo JA, et al. Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. J Clin Pharmacol. 2012 Jan;52(1 Suppl):91S–108S.
   PubMedGoogle Scholar
• Zhuang X, Lu C. PBPK modeling and simulation in drug research and development. Acta Pharm Sin B. 2016 Sep;6(5):430–440.
   PubMed Web of Science ®Google Scholar
• Peters SA. Physiologically-based pharmacokinetic (PBPK) modeling and simulations: principles, methods, and applications in the pharmaceutical industry. Hoboken, New Jersey: John Wiley & Sons, Inc.; 2012.
   Google Scholar
• Wong H, Chow TW. Physiologically based pharmacokinetic modeling of therapeutic proteins. J Pharm Sci. 2017 Sep;106(9):2270–2275.
   PubMed Web of Science ®Google Scholar
• Danhof M, de Jongh J, De Lange EC, et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol. 2007;47:357–400.
   PubMed Web of Science ®Google Scholar
• Niederalt C, Kuepfer L, Solodenko J, et al. A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim. J Pharmacokinet Pharmacodyn. 2018 Apr;45(2):235–257.
   PubMed Web of Science ®Google Scholar
• Thygesen P, Macheras P, Van Peer A. Physiologically-based PK/PD modelling of therapeutic macromolecules. Pharm Res. 2009 Dec;26(12):2543–2550.
   PubMed Web of Science ®Google Scholar
• Kaczmarek JC, Kowalski PS, Anderson DG. Advances in the delivery of RNA therapeutics: from concept to clinical reality. Genome Med. 2017 Jun 27;9(1):60.
   PubMed Web of Science ®Google Scholar
• Vizirianakis IS, Mystridis GA, Avgoustakis K, et al. Enabling personalized cancer medicine decisions: the challenging pharmacological approach of PBPK models for nanomedicine and pharmacogenomics (Review). Oncol Rep. 2016 Apr;35(4):1891–1904.
   PubMed Web of Science ®Google Scholar
• FDA. Physiologically-Based Pharmacokinetic (PBPK) Modeling of Nanomedicine 2014 [cited 2018 Nov 27]. Available from: https://www.accessdata.fda.gov/scripts/fdatrack/view/track_project.cfm?id=NCTR-OSC-PM-PBPK-Modeling-of-Nanomedicine&program=nctr&source=govdelivery&utm_medium=email&utm_source=govdelivery
   Google Scholar
• Hartmanshenn C, Scherholz M, Androulakis IP. Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine. J Pharmacokinet Pharmacodyn. 2016 Oct;43(5):481–504.
   PubMed Web of Science ®Google Scholar
• Vogenberg FR, Isaacson Barash C, Pursel M. Personalized medicine: part 1: evolution and development into theranostics. P T. 2010 Oct;35(10):560–576.
   PubMedGoogle Scholar
• Herrmann IK, Rosslein M. Personalized medicine: the enabling role of nanotechnology. Nanomedicine (Lond). 2016 Jan;11(1):1–3.
   PubMed Web of Science ®Google Scholar
• Jaroch K, Jaroch A, Bojko B. Cell cultures in drug discovery and development: the need of reliable in vitro-in vivo extrapolation for pharmacodynamics and pharmacokinetics assessment. J Pharm Biomed Anal. 2018 Jan;5(147):297–312.
   Google Scholar
• Edmondson R, Broglie JJ, Adcock AF, et al. Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. Assay Drug Dev Technol. 2014 May;12(4):207–218.
   PubMed Web of Science ®Google Scholar
• Huang Y, Zhang XF, Gao G, et al. 3D bioprinting and the current applications in tissue engineering. Biotechnol J. 2017 Aug;12(8):1600734.
   Web of Science ®Google Scholar
• Li J, Chen M, Fan X, et al. Recent advances in bioprinting techniques: approaches, applications and future prospects. J Transl Med. 2016 Sep;20(14):271.
   Google Scholar
• Mandrycky C, Wang Z, Kim K, et al. 3D bioprinting for engineering complex tissues. Biotechnol Adv. 2016;34(4):422–434.
   PubMed Web of Science ®Google Scholar
• Peng W, Datta P, Ayan B, et al. 3D bioprinting for drug discovery and development in pharmaceutics. Acta Biomater. 2017 Jul 15;57:26–46.
   PubMed Web of Science ®Google Scholar
• Moon S, Hasan SK, Song YS, et al. Layer by layer three-dimensional tissue epitaxy by cell-laden hydrogel droplets. Tissue Eng Part C Methods. 2010 Feb;16(1):157–166.
   PubMed Web of Science ®Google Scholar
• Lee W, Pinckney J, Lee V, et al. Three-dimensional bioprinting of rat embryonic neural cells. Neuroreport. 2009 May 27;20(8):798–803.
   PubMed Web of Science ®Google Scholar
• Jia W, Gungor-Ozkerim PS, Zhang YS, et al. Direct 3D bioprinting of perfusable vascular constructs using a blend bioink. Biomaterials. 2016;106:58–68.
   PubMed Web of Science ®Google Scholar
• Jeon H, Kang K, Park SA, et al. Generation of multilayered 3D structures of HepG2 cells using a bio-printing technique. Gut Liver. 2017 Jan 15;11(1):121–128.
   PubMed Web of Science ®Google Scholar
• Shim JH, Jang KM, Hahn SK, et al. Three-dimensional bioprinting of multilayered constructs containing human mesenchymal stromal cells for osteochondral tissue regeneration in the rabbit knee joint. Biofabrication. 2016 Feb 4;8(1):014102.
   PubMed Web of Science ®Google Scholar
• Verheijen M, Schrooders Y, Gmuender H, et al. Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184–192.
   PubMed Web of Science ®Google Scholar
• Charbe N, McCarron PA, Tambuwala MM. Three-dimensional bio-printing: a new frontier in oncology research. World J Clin Oncol. 2017 Feb 10;8(1):21–36.
   PubMed Web of Science ®Google Scholar
• Boczkowski D, Nair SK, Snyder D, et al. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med. 1996 Aug 1;184(2):465–472.
   PubMed Web of Science ®Google Scholar
• Conry RM, LoBuglio AF, Wright M, et al. Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res. 1995 Apr 1;55(7):1397–1400.
   PubMed Web of Science ®Google Scholar
• Hoerr I, Obst R, Rammensee HG, et al. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol. 2000 Jan;30(1):1–7.
   PubMed Web of Science ®Google Scholar
• Jirikowski GF, Sanna PP, Maciejewski-Lenoir D, et al. Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA. Science. 1992 Feb 21;255(5047):996–998.
   PubMed Web of Science ®Google Scholar
• Pascolo S. The messenger’s great message for vaccination. Expert Rev Vaccines. 2015 Feb;14(2):153–156.
   PubMed Web of Science ®Google Scholar
• Tavernier G, Andries O, Demeester J, et al. mRNA as gene therapeutic: how to control protein expression. J Control Release. 2011 Mar 30;150(3):238–247.
   PubMed Web of Science ®Google Scholar
• Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science. 1990 Mar 23;247(4949 Pt 1):1465–1468.
   PubMed Web of Science ®Google Scholar
• Xiong Q, Lee GY, Ding J, et al. Biomedical applications of mRNA nanomedicine [journal article]. Nano Res. 2018 October 01;11(10):5281–5309.
   PubMed Web of Science ®Google Scholar
• Plews JR, Li J, Jones M, et al. Activation of pluripotency genes in human fibroblast cells by a novel mRNA based approach. PLoS One. 2010 Dec 30;5(12):e14397.
   PubMed Web of Science ®Google Scholar
• Guan S, Rosenecker J. Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems. Gene Ther. 2017 Mar;24(3):133–143.
   PubMed Web of Science ®Google Scholar
• Zhang R, Billingsley MM, Mitchell MJ. Biomaterials for vaccine-based cancer immunotherapy. J Control Release. 2018 Oct;9(292):256–276.
   Google Scholar
• Weide B, Pascolo S, Scheel B, et al. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother. 2009 Jun;32(5):498–507.
   PubMed Web of Science ®Google Scholar
• Rittig SM, Haentschel M, Weimer KJ, et al. Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther. 2011 May;19(5):990–999.
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Porter FW, et al. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018 Apr;17(4):261–279.
   PubMed Web of Science ®Google Scholar
• Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res off J Am Assoc Cancer Res. 2011 Jun 1;17(11):3520–3526.
   PubMed Web of Science ®Google Scholar
• Zhou WZ, Hoon DS, Huang SK, et al. RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization. Hum Gene Ther. 1999 Nov 1;10(16):2719–2724.
   PubMed Web of Science ®Google Scholar
• David AL, Peebles DM, Gregory L, et al. Clinically applicable procedure for gene delivery to fetal gut by ultrasound-guided gastric injection: toward prenatal prevention of early-onset intestinal diseases. Hum Gene Ther. 2006 Jul;17(7):767–779.
   PubMed Web of Science ®Google Scholar
• Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017 Jul 13;547(7662):222–226.
   PubMed Web of Science ®Google Scholar
• Chen P, Liu X, Sun Y, et al. Dendritic cell targeted vaccines: recent progresses and challenges. Hum Vaccin Immunother. 2016 Mar 3;12(3):612–622.
   PubMed Web of Science ®Google Scholar
• Kranz LM, Diken M, Haas H, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016 Jun 16;534(7607):396–401.
   PubMed Web of Science ®Google Scholar
• Diken M, Kreiter S, Kloke B, et al. Current developments in actively personalized cancer vaccination with a focus on RNA as the drug format. Prog Tumor Res. 2015;42:44–54.
   PubMed Web of Science ®Google Scholar
• Castle JC, Kreiter S, Diekmann J, et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 2012 Mar 1;72(5):1081–1091.
   PubMed Web of Science ®Google Scholar
• Matsushita H, Vesely MD, Koboldt DC, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012 Feb 8;482(7385):400–404.
   PubMed Web of Science ®Google Scholar
• Gal J, Milano G, Ferrero JM, et al. Optimizing drug development in oncology by clinical trial simulation: why and how? Brief Bioinform. 2017 May 29;19(6):1203–1217.
   Web of Science ®Google Scholar
• Doudican NA, Kumar A, Singh NK, et al. Personalization of cancer treatment using predictive simulation. J Transl Med. 2015 Feb;1(13):43.
   Google Scholar
• Drusbosky LM, Cogle CR. Computational modeling and treatment identification in the myelodysplastic syndromes [Review]. Curr Hematol Malig Rep. 2017 Oct;12(5):478–483.
   PubMed Web of Science ®Google Scholar
• Drusbosky L, Medina C, Martuscello R, et al. Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patients. Leukemia Res 2017Jan;52:1–7
   PubMed Web of Science ®Google Scholar
• Doestzada M, Vila AV, Zhernakova A, et al. Pharmacomicrobiomics: a novel route towards personalized medicine? Protein Cell. 2018 May;9(5):432–445.
   PubMed Web of Science ®Google Scholar
• Liu Z, Delavan B, Roberts R, et al. Lessons learned from two decades of anticancer drugs. Trends Pharmacol Sci. 2017 Oct;38(10):852–872.
   PubMed Web of Science ®Google Scholar
• Marigorta UM, Rodriguez JA, Gibson G, et al. Replicability and prediction: lessons and challenges from GWAS. Trends Genet. 2018 Jul;34(7):504–517.
   PubMed Web of Science ®Google Scholar
• Silverio A, Cavallo P, De Rosa R, et al. Big health data and cardiovascular diseases: a challenge for research, an opportunity for clinical care. Front Med (Lausanne). 2019;6:36.
   PubMed Web of Science ®Google Scholar
• Lau E, Wu JC, Omics B. Data, and precision medicine in cardiovascular sciences. Circ Res. 2018 Apr 27;122(9):1165–1168.
   PubMed Web of Science ®Google Scholar
• Hulsen T, Jamuar SS, Moody AR, et al. From big data to precision medicine. Front Med (Lausanne). 2019;6:34.
   PubMed Web of Science ®Google Scholar
• Olivera P, Danese S, Jay N, et al. Big data in IBD: a look into the future. Nat Rev Gastroenterol Hepatol. 2019 Jan 18.
   PubMed Web of Science ®Google Scholar
• Bhatt DK, Mehrotra A, Gaedigk A, et al. Age- and genotype-dependent variability in the protein abundance and activity of six major uridine diphosphate-glucuronosyltransferases in human liver. Clin Pharmacol Ther. 2019 January 105(1):131-141.
   PubMed Web of Science ®Google Scholar